OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Klisovic on the Impact of Momelotinib on Myelofibrosis Management

May 9th 2024

Rebecca Klisovic, MD, discusses updates with JAK inhibitors, highlighting factors that inform JAK inhibitor selection in myelofibrosis.

Dr Hauschild on Ongoing Research With Adjuvant Immunotherapy in CSCC

May 9th 2024

Axel Hauschild, MD, PhD, discusses research with adjuvant immunotherapy in CSCC and immunotherapy indications in basal cell carcinoma.

Dr Porter on the Efficacy of CAR T-Cell Therapy in Relapsed/Refractory CLL

May 9th 2024

David L. Porter, MD, discusses the use of CAR T-cell therapy alone or in combination regimens in relapsed/refractory chronic lymphocytic leukemia.

Dr Brown on Ongoing Trials Targeting the RAS/MAPK Pathway in Ovarian Cancer

May 9th 2024

Jubilee Brown, MD, discusses ongoing investigations into treatments that target the RAS/MAPK pathway in patients with ovarian cancer.

Dr Deng on BTK Inhibitors vs Venetoclax-Based Treatment Regimens in CLL/SLL

May 9th 2024

Changchun Deng, MD, PhD, discusses considerations for covalent BTK inhibitors vs venetoclax-based treatment regimens for chronic lymphocytic leukemia.

Dr Chambers on FDA-Approved PARP Inhibitors in the Ovarian Cancer Treatment Arena

May 8th 2024

Laura J Chambers, DO, discusses currently approved PARP inhibitors that are considered for use in ovarian cancer.

Dr Cosgrove on the FDA Approval of Mirvetuximab Soravtansine for Frα+ Ovarian Cancer

May 8th 2024

Casey M. Cosgrove, MD, discusses the FDA approval of mirvetuximab soravtansine for adult patients with Frα+, platinum-resistant ovarian cancer.

Dr Mujumdar on Awareness Initiatives to Address Unmet Needs in Ovarian Cancer

May 8th 2024

Vaidehi Mujumdar, MD, discusses how awareness initiatives can help address unmet needs in patients with ovarian cancer on World Ovarian Cancer Day.

Dr Piulats on the Rationale For Evaluating Predictive Biomarkers for Talazoparib/Enzalutamide in mCRPC

May 8th 2024

Josep Maria Piulats Rodriguez, MD, PhD, discusses the rationale for identifying predictive biomarkers for talazoparib plus enzalutamide in mCRPC.

Dr Koehne on the Use of Chemotherapy-Only Conditioning Regimens in Hematologic Malignancies

May 8th 2024

Guenther Koehne, MD, PhD, discusses the use of chemotherapy-only conditioning regimens for patients with hematologic malignancies undergoing transplant.

Dr Cherng on Approvals of Epcoritamab and Glofitamab for R/R DLBCL

May 8th 2024

Hua-Jay "Jeff" Cherng on approvals of epcoritamab and glofitamab for relapsed/refractory DLBCL

Dr Jurcic on the Evolution of Combination Therapies in the Management of Myelofibrosis

May 8th 2024

Joseph G. Jurcic, MD, discusses the evolution of combination therapies in the management of myelofibrosis.

Dr Beckermann on Targeting TREM2 in the Treatment of ccRCC

May 7th 2024

Kathryn Beckermann, MD, PhD, discusses ongoing studies investigating the role of TREM2 in the treatment of patients with clear cell renal cell carcinoma.

Dr Iyer on the Mechanism of Action of Imetelstat in Lower-Risk MDS

May 7th 2024

Sunil Iyer, MD, discusses the mechanism of action of imetelstat in patients with lower-risk myelodysplastic syndrome with anemia.

Dr Crane on the Ongoing Investigation of PARP Inhibitor Combinations in Ovarian Cancer

May 7th 2024

Dr Aldoss on the Utility of Ponatinib in Ph+ ALL

May 6th 2024

Ibrahim Aldoss, MD, discusses the utility of ponatinib in the phase 3 PhALLCON trial for patients with newly diagnosed, Ph+ acute lymphoblastic leukemia.

Dr Battiwalla on Advancements in the Multiple Myeloma Treatment Paradigm

May 6th 2024

Minoo Battiwalla, MD, discusses recent advancements in the multiple myeloma treatment paradigm.

Dr Siefker-Radtke on the Safety of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

May 6th 2024

Arlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.

Dr Lenz on the Association Between HER2 Expression and Treatment Outcomes in mCRC

May 6th 2024

Heinz-Josef Lenz, MD, FACP, discusses the association between HER2 expression and treatment outcomes in metastatic colorectal cancer.

Dr Garje on Selecting Between PARP Inhibitor Combinations in mCRPC

May 4th 2024

Rohan Garje, MD, discusses considerations when choosing between FDA-approved PARP inhibitor–based combinations for patients with mCRPC.